239 related articles for article (PubMed ID: 28489074)
1. Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Sinha R; Winer AG; Chevinsky M; Jakubowski C; Chen YB; Dong Y; Tickoo SK; Reuter VE; Russo P; Coleman JA; Sander C; Hsieh JJ; Hakimi AA
Nat Commun; 2017 May; 8():15165. PubMed ID: 28489074
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
3. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
5. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
[TBL] [Abstract][Full Text] [Related]
6. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
[TBL] [Abstract][Full Text] [Related]
8. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.
Bailey ST; Smith AM; Kardos J; Wobker SE; Wilson HL; Krishnan B; Saito R; Lee HJ; Zhang J; Eaton SC; Williams LA; Manocha U; Peters DJ; Pan X; Carroll TJ; Felsher DW; Walter V; Zhang Q; Parker JS; Yeh JJ; Moffitt RA; Leung JY; Kim WY
Nat Commun; 2017 Jun; 8():15770. PubMed ID: 28593993
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
10. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.
Weng S; DiNatale RG; Silagy A; Mano R; Attalla K; Kashani M; Weiss K; Benfante NE; Winer AG; Coleman JA; Reuter VE; Russo P; Reznik E; Tickoo SK; Hakimi AA
Eur Urol; 2021 Apr; 79(4):468-477. PubMed ID: 33046271
[TBL] [Abstract][Full Text] [Related]
11. Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron.
Büttner F; Winter S; Rausch S; Reustle A; Kruck S; Junker K; Stenzl A; Agaimy A; Hartmann A; Bedke J; Schwab M; Schaeffeler E
Eur Urol; 2015 Dec; 68(6):1016-20. PubMed ID: 26072688
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression.
Cuadros T; Trilla E; Vilà MR; de Torres I; Vilardell J; Messaoud NB; Salcedo M; Sarró E; López-Hellin J; Blanco A; Mir C; Ramón y Cajal S; Itarte E; Morote J; Meseguer A
Eur J Cancer; 2013 May; 49(8):2034-47. PubMed ID: 23352434
[TBL] [Abstract][Full Text] [Related]
14. Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity.
Sanfrancesco JM; Eble JN; Grignon DJ; Wang M; Zhang S; Sundaram CP; Idrees MT; Pili R; Kouba E; Cheng L
Mol Carcinog; 2017 Nov; 56(11):2527-2537. PubMed ID: 28667776
[TBL] [Abstract][Full Text] [Related]
15. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
[TBL] [Abstract][Full Text] [Related]
16. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas.
Zhu B; Poeta ML; Costantini M; Zhang T; Shi J; Sentinelli S; Zhao W; Pompeo V; Cardelli M; Alexandrov BS; Otlu B; Hua X; Jones K; Brodie S; Dabrowska ME; Toro JR; Yeager M; Wang M; Hicks B; Alexandrov LB; Brown KM; Wedge DC; Chanock S; Fazio VM; Gallucci M; Landi MT
Nat Commun; 2020 Jun; 11(1):3096. PubMed ID: 32555180
[TBL] [Abstract][Full Text] [Related]
17. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
Durinck S; Stawiski EW; Pavía-Jiménez A; Modrusan Z; Kapur P; Jaiswal BS; Zhang N; Toffessi-Tcheuyap V; Nguyen TT; Pahuja KB; Chen YJ; Saleem S; Chaudhuri S; Heldens S; Jackson M; Peña-Llopis S; Guillory J; Toy K; Ha C; Harris CJ; Holloman E; Hill HM; Stinson J; Rivers CS; Janakiraman V; Wang W; Kinch LN; Grishin NV; Haverty PM; Chow B; Gehring JS; Reeder J; Pau G; Wu TD; Margulis V; Lotan Y; Sagalowsky A; Pedrosa I; de Sauvage FJ; Brugarolas J; Seshagiri S
Nat Genet; 2015 Jan; 47(1):13-21. PubMed ID: 25401301
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
